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BACKGROUND. A defining pathophysiologic feature of sepsis is profound apoptosisinduced death and depletion of CD4+ and CD8+ T cells. Interleukin-7 (IL-7) is an
antiapoptotic common g-chain cytokine that is essential for lymphocyte proliferation and
survival. Clinical trials of IL-7 in over 390 oncologic and lymphopenic patients showed that
IL-7 was safe, invariably increased CD4+ and CD8+ lymphocyte counts, and improved
immunity.
METHODS. We conducted a prospective, randomized, double-blind, placebo-controlled
trial of recombinant human IL-7 (CYT107) in patients with septic shock and severe
lymphopenia. Twenty-seven patients at academic sites in France and the United States
received CYT107 or placebo for 4 weeks. Primary aims were to determine the safety of
CYT107 in sepsis and its ability to reverse lymphopenia.
RESULTS. CYT107 was well tolerated without evidence of inducing cytokine storm or
worsening inflammation or organ dysfunction. CYT107 caused a 3- to 4-fold increase in
+
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absolute lymphocyte counts and in circulating CD4 and CD8 T cells that persisted for
weeks after drug administration. CYT107 also increased T cell proliferation and activation.
CONCLUSIONS. This is the first trial of an immunoadjuvant therapy targeting defects in
adaptive immunity in patients with sepsis. CYT107 reversed […]
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BACKGROUND. A defining pathophysiologic feature of sepsis is profound apoptosis-induced death
and depletion of CD4+ and CD8+ T cells. Interleukin-7 (IL-7) is an antiapoptotic common γ-chain
cytokine that is essential for lymphocyte proliferation and survival. Clinical trials of IL-7 in over 390
oncologic and lymphopenic patients showed that IL-7 was safe, invariably increased CD4+ and CD8+
lymphocyte counts, and improved immunity.
METHODS. We conducted a prospective, randomized, double-blind, placebo-controlled trial of
recombinant human IL-7 (CYT107) in patients with septic shock and severe lymphopenia. Twentyseven patients at academic sites in France and the United States received CYT107 or placebo for
4 weeks. Primary aims were to determine the safety of CYT107 in sepsis and its ability to reverse
lymphopenia.
RESULTS. CYT107 was well tolerated without evidence of inducing cytokine storm or worsening
inflammation or organ dysfunction. CYT107 caused a 3- to 4-fold increase in absolute lymphocyte
counts and in circulating CD4+ and CD8+ T cells that persisted for weeks after drug administration.
CYT107 also increased T cell proliferation and activation.
CONCLUSIONS. This is the first trial of an immunoadjuvant therapy targeting defects in adaptive
immunity in patients with sepsis. CYT107 reversed the marked loss of CD4+ and CD8+ immune
effector cells, a hallmark of sepsis and a likely key mechanism in its morbidity and mortality. CYT107
represents a potential new way forward in the treatment of patients with sepsis by restoring adaptive
immunity. Such immune-based therapy should be broadly protective against diverse pathogens
including multidrug resistant bacteria that preferentially target patients with impaired immunity.
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Introduction
A defining feature of sepsis is a profound apoptosis-induced depletion of lymphocytes (1–4). Postmortem
studies of patients who died of sepsis demonstrate extensive loss of lymphocytes in spleens, intestines, and
other organs (1, 4). The tissue lymphocyte depletion occurring during sepsis is accompanied by a decrease
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Figure 1. Trial enrollment details. Details on patient enrollment,
randomization, allocation, and follow-up and analysis are presented.
Medical, Surgical, Neurosurgical, and Cardiothoracic Intensive Care
Units were screened daily Monday through Friday for patients on
antibiotics and vasopressors. After identifying patients in presumed
septic shock, patients were further screened for inclusion and exclusion criteria as per the protocol.

in the absolute number of circulating lymphocytes, i.e., lymphopenia (5–8). This lymphopenia that is present in sepsis consists of
the loss of many different classes of lymphocytes including CD4+
and CD8+ T cells, B cells, and natural killer cells (1, 9). CD4+ T
cell counts in patients with sepsis are often as low as that occurring in patients with life-threatening AIDS (10). Lymphocytes are
essential for an effective host defense against invading pathogens
(11). Studies in patients who have undergone bone marrow or
solid organ transplantation show a direct correlation between low
CD4+ cell counts and the incidence of new onset opportunistic
infections and death (12, 13). Similarly, numerous studies have
shown that septic patients with more severe and persistent lymphopenia have a higher mortality compared with septic patients
who are either not lymphopenic or who have a lesser degree of
lymphopenia (5–8).
A key question is whether the lymphocyte depletion in sepsis
is merely an epiphenomenon or whether it plays a central role
in lethality in sepsis. Several mechanistic studies have addressed
this critical issue. Studies by multiple independent laboratories
showed that mice whose lymphocytes were resistant to sepsisinduced apoptosis because of either overexpression of the antiapoptotic protein Bcl-2 or deletion of the proapoptotic protein
Bim have improved survival in sepsis (14–19). Furthermore, studies also demonstrate that adoptive transfer
of lymphocytes that are resistant to sepsis-induced apoptosis, but not adoptive transfer of normal apoptosis-susceptible lymphocytes, improves sepsis survival (15). Collectively, these animal studies together with
patient studies showing a close correlation between the degree of lymphopenia and survival strongly suggest
that the extensive lymphocyte depletion is fundamental to the pathophysiology of sepsis (20, 21).
Interleukin-7 (IL-7) is a potent Bcl-2–inducing, antiapoptotic, common γ-chain cytokine that is required
for lymphocyte survival and expansion (22–24). In addition to its antiapoptotic properties, IL-7 induces
robust proliferation of CD4+ and CD8+ T cells. Given its ability to prevent lymphocyte apoptosis, induce
lymphocyte proliferation, and improve lymphocyte function, IL-7 has been tested by several groups in
animal models of sepsis (25–27). These studies showed that IL-7 prevented lymphocyte apoptosis, restored
CD4+ and CD8+ T cell function, and improved survival in animal models of bacterial and fungal sepsis
(25–27). Importantly, IL-7 was also effective in preventing lymphocyte apoptosis, improving T cell cytokine
production, and restoring lymphocyte metabolism in ex vivo studies conducted on peripheral blood from
patients with septic shock (28, 29).
Although not currently approved for clinical use, CYT107, a glycosylated recombinant human IL-7,
has been administered in clinical trials to over 390 adult and pediatric patients for a variety of disorders
including HIV, idiopathic lymphopenia, cancer, hepatitis C, and bone marrow reconstitution following
stem cell transplantation (30–35). In clinical trials of HIV-infected patients who had lymphopenia despite
antiretroviral therapy, CYT107 caused a 2- to 4-fold dose-dependent increase in circulating CD4+ and
CD8+ T cells (31). CYT107 consistently increased circulating lymphocyte counts and was well tolerated,
with rash being the only serious adverse effect (30–35). Recently, CYT107 was administered on a compassionate basis to patients with lymphopenia and John Cunningham (JC) virus–induced progressive multifocal leukoencephalopathy (36, 37). In this desperate setting, CYT107 typically increased lymphocyte counts,
decreased JC viral load, and led to resolution of neurologic symptoms (36, 37).
insight.jci.org   https://doi.org/10.1172/jci.insight.98960
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Figure 2. CYT107 increases absolute lymphocyte counts. (A)
Patients were treated with 10 μg/kg CYT107, a recombinant human
interleukin-7 (IL-7) using 2 different dosing regimens. Both CYT107treated groups received CYT107 twice a week for the first week.
Thereafter, one group was treated with CYT107 once a week (low
frequency) while the second CYT107 treated group was treated with
CYT107 twice a week (high frequency). Therapy with CYT107 was
continued for a total of 4 weeks or until the patient was discharged
from the hospital. The maximum number of doses of CYT107 that a
patient could receive was 5 or 8 doses respectively for the low- and
high-dose regimens of CYT107. All patients received injections twice
a week. (B) The CYT107 treatment effect on average absolute lymphocyte counts (ALCs) was significant for both high- and low-frequency treatment regimens. The gray-shaded region represents the
upper and lower limit of normal for ALCs. The CYT107 low-frequency
group (red color) was greater than the placebo-treated group at
days 15 and 42, and the CYT107 high-frequency group (blue color)
was greater than placebo-treated at days 22 and 29. *P < 0.05,
**P < 0.01, ***P < 0.001. Statistical tests were conducted using a
Wald-type multiple-degree-of-freedom method. Dark arrowhead
represents the last day of treatment. Values reported are mean ±
SEM. n = 10, 8, and 9 for placebo, low-frequency CYT107-treated,
and high-frequency CYT107-treated patients, respectively. (C) The
CYT107 treatment effect on ALCs is displayed for each patient over
the study duration.

We conducted a prospective, multicenter, randomized, double-blind, placebo-controlled phase IIb
trial of CYT107 in patients with septic shock and severe lymphopenia of 900 lymphocytes/μl or lower.
Clinical immunoadjuvant trials to date have targeted innate immunity. Importantly, this study represents the first immunotherapeutic trial to our knowledge focused on augmenting the adaptive immune
system in patients with sepsis. The primary purpose of the trial was to assess the safety and tolerability of CYT107 in this critically ill patient population with sepsis. The second goal of the trial was to
determine if CYT107 could reverse the profound sepsis-induced lymphopenia and improve the absolute
numbers of circulating CD4+ and CD8+ T cells. Additional aims of the study were to examine the
effect of CYT107 on markers of lymphocyte proliferation and activation, and incidence of secondary,
hospital-acquired infections.
Herein we show that therapy with CYT107 in septic patients was well tolerated without any evidence
of inducing a cytokine storm or worsening ongoing inflammation. CYT107 was effective in reversing the
profound sepsis-induced lymphopenia and caused a 3- to 4-fold increase in the absolute lymphocyte count
and in circulating CD4+ and CD8+ T cells. Thus, CYT107 reversed a key pathogenic hallmark of sepsis
that likely plays a major role in sepsis-associated morbidity and mortality. Given CYT107’s extensive
safety record in critically ill patients, its ability to improve survival in multiple animal models of sepsis,
and its documented efficacy in patients with life-threatening viral infections, additional clinical trials of
CYT107 in sepsis should be conducted. Targeting the dysfunctional adaptive immune system in sepsis
with IL-7 may represent a new way forward against this highly lethal disease.

Results
See supplemental materials and methods for additional details.
insight.jci.org   https://doi.org/10.1172/jci.insight.98960
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Table 1. Clinical characteristics
Age, mean (range)
Gender, M/F
Baseline SOFA score, mean (range)
Baseline APACHE II score, mean (range)
Infections, number:
Abdominal infection
Endocarditis
Epidural abscess
Mediastinitis
Necrotizing fasciitis
Pneumonia
Urinary tract infection
Days in ICU, median (range)

Placebo (n = 10)

IL-7 (n = 17)

P value

56 (33–77)
8/2
9 (3–16)
17 (3–30)

65 (33–82)
13/4
7 (2–12)
14 (8–23)

0.197
0.831
0.194
0.461
0.947

3
0
1
1
1
3
1
19 (7–43)

6
1
0
1
2
6
1
16 (4–70)

0.939

SOFA, sequential organ failure assessment; APACHE II, acute physiologic assessment and chronic health evaluation II.

Study design and participants
This double-blind, randomized, placebo-controlled phase IIb trial of CYT107 was conducted at 4 academic
sites, with 2 sites in the United States (Vanderbilt University School of Medicine and Washington University School of Medicine) and 2 sites in France (University Hospital of Limoges and Edouard Herriot Hospital). Following FDA approval of the study, the Institutional Review Boards at Vanderbilt University and
Washington University approved the protocols. For France, the study protocol was approved by the Committee for the Protection of Persons (CPP) and the National Agency for Drug Safety (ANSM). All patients
or their legal representatives gave written informed consent prior to inclusion in the study. Both the US and
French teams used identical protocols registered on Clinicaltrials.gov, NCT02640807 and NCT02797431
respectively, for the 2 countries. The data from all 4 sites were combined for analysis.
Inclusion criteria. Twenty-seven patients who met the criteria for vasopressor-dependent septic shock
with at least one organ failure defined by a sequential organ failure assessment (SOFA) score of 2 or higher
persisting at 48–120 hours after intensive care unit (ICU) admission were enrolled into the study (Figure 1)
(38). See supplemental materials for further patient enrollment details and additional inclusion and exclusion criteria. An additional entry criterion for inclusion was lymphopenia with an absolute lymphocyte
count of 900 lymphocytes/μl or lower obtained within 24–48 hours prior to providing consent. Lymphopenia was selected as an inclusion criterion because persistent lymphopenia identifies patients with immunosuppression and a higher mortality (5–8).
Exclusion criteria. Patients were excluded for evidence of autoimmune disorders, active hematological
diseases, cancer with current chemo- or radiotherapy, treatment with corticosteroids equivalent to a dose of
300 mg/day or higher of hydrocortisone, and treatment with immunosuppressive medications.
CYT107 dosing regimens. Patients received either CYT107 (glycosylated recombinant human IL-7) or placebo via the intramuscular route. There were 2 different dosing regimens for CYT107; both groups received
10 μg/kg CYT107 twice a week for the first week (Figure 2A). Thereafter, one group was treated with 10 μg/
kg CYT107 once a week (low frequency), while the second CYT107-treated group was treated with CYT107
10 μg/kg twice a week (high frequency). Therapy with CYT107 was continued for a total of 4 weeks (last
dose administered on day 25 after trial initiation) or until the patient was discharged from the hospital. The
maximum number of doses of CYT107 that a patient could receive was 5 or 8 doses respectively for the lowand high-dose regimens of CYT107. All patients were injected twice a week with either placebo or CYT107
to maintain blinding of investigators and treating physicians (see Figure 2A for protocol).
Patient characteristics. There were no significant differences in the patient age, gender, site of infection,
ICU days, SOFA, or acute physiologic assessment and chronic health evaluation (APACHE) II scores (Table
1). The most common sites of infection were pneumonia and abdominal infection (peritonitis). Pneumonia
was present in 6 of 17 (35%) CYT107-treated patients and 3 of 10 (30%) of placebo-treated patients. Peritonitis was present in 6 of 17 (35%) of CYT107-treated patients and 3 of 10 (30%) placebo-treated patients.
insight.jci.org   https://doi.org/10.1172/jci.insight.98960
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Figure 3. CYT107 increased CD4+ and CD8+ T cell counts. (A)
The effect of CYT107 on the averaged CD4+ and CD8+ T cell
counts, considered for study duration, was significant for
both CD4+ and CD8+ T cells. The low-frequency regimen (red
color) significantly increased CD4+ and the high-frequency
regimen (blue color) increased CD8+ T cells compared with
placebo. Low-frequency CYT107 therapy increased CD4+ T
cells at days 8, 15, and 22. High-frequency CYT107 therapy
increased CD8+ T cells at day 42. *P < 0.05, **P < 0.01. Statistical tests were conducted using a Wald-type multipledegree-of-freedom method. Values reported are mean ±
SEM. n = 10, 8, and 9 for placebo, low-frequency CYT107, and
high-frequency CYT107-treated patients, respectively. (B)
The effect of CYT107 on individual patient CD4+ and CD8+
T cell counts is presented. Note that the patients at US
sites had quantification of CD4+ and CD8+ T cell counts for 6
weeks, while the patients at French sites had quantification
out to 4 weeks only.

Safety and tolerability of CYT107
Of the 27 patients who were randomized into the study, 9 patients were randomized to the high-frequency
regimen, 8 patients were randomized to the low-frequency CYT107 regimen, and 10 patients were randomized
into placebo. The mean number of doses of CYT107 that the patients in the low- and high-frequency protocols
received was 4.3 ± 0.3 and 6.1 ± 0.8, respectively. CYT107 was well tolerated with no evidence of induction of
cytokine storm or excessive inflammation. Specifically, administration of CYT107 was not temporally associated with new onset or worsening of existing fever, tachycardia, hypotension, or evidence of organ injury.
Serial quantification of the effect of CYT107 on the proinflammatory cytokines TNF-α and IL-6 and the
antiinflammatory cytokine IL-10 was performed on patient plasma samples (Supplemental Figure 1, A–F;
supplemental material available online with this article; https://doi.org/10.1172/jci.insight.98960DS1).
The baseline value for TNF-α in patients, i.e., prior to treatment with CYT107 or placebo, was 17.5 ± 3.1
pg/ml (n = 22 patients). Most CYT107-treated patients showed no increase in TNF-α above the beginning
baseline values, while 2 patients had a transient increase at one time point (Supplemental Figure 1C). Baseline IL-6 levels were elevated in septic patients, i.e., 158.5 ± 30.5 pg/ml (n = 22 patients). The majority of
CYT107-treated patients showed no effect of drug administration on IL-6. There was a modest increase in
IL-6 levels in 2 CYT107-treated patients but also in 1 placebo-treated patient (Supplemental Figure 1A).
Baseline IL-10 levels were elevated in septic patients, i.e., 99.0 ± 17.0 pg/ml (n = 22 patients). There was an
increase in IL-10 in 2 CYT107-treated patients and in 1 placebo-treated patient (Supplemental Figure 1B).
Serial laboratory testing for serum creatinine, a measure of renal function, showed no difference in
CYT107- versus placebo-treated patients (Supplemental Figure 2). Similarly, there were no differences in
serial liver function tests in CYT107- versus placebo-treated patients (Supplemental Figure 3).
The only adverse effects attributable to CYT107 were injection site reactions varying from a grade 1–3
rash, as scored according to the Division of AIDS (DAIDS) version 2 toxicity scale. Most injection site
reactions that occurred were small and less than 0.5 to 2.0 cm in diameter (grade 1). Six patients developed
a grade 2–3 injection site reaction consisting of a raised red rash without vesicles or blistering involving
20%–70% of the surface area of one upper or lower extremity. Despite the rash, 2 patients continued to
receive CYT107 for the entire 8-dose regimen. CYT107 therapy was discontinued in 4 patients for progression of the rash as follows: one patient discontinued after 3 doses, one patient discontinued after 4 doses,
one patient discontinued after 6 doses, and one patient discontinued after 7 doses. Biopsies of skin rashes in 2 of the patients showed CD3-positive lymphocytic infiltration (Supplemental Figure 4). All rashes
resolved without complication after completion of CYT107.
insight.jci.org   https://doi.org/10.1172/jci.insight.98960
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Figure 4. CYT107 causes an initial drop in circulating CD8+ T cells.
CYT107 caused an early transient decrease in CD4+ and CD8+ T cells
prior to significantly increasing lymphocyte counts. Individual
septic patients treated with low- and high-dose CYT107 regimens
are depicted in red and blue color, respectively. The placebo-treated
patients are presented as a group and depicted with a solid black line.
At day 4, CD8+ T cells were significantly decreased in patients receiving low-frequency regimen CYT107 (red color) compared with placebo
(P ≤ 0.05). The effect of CYT107 to decrease CD4+ T cells did not quite
achieve statistical significance. Statistical tests were conducted using
a Wald-type multiple-degree-of-freedom method. Values reported are
mean ± SEM. n = 10, 8, and 9 for placebo, low-frequency CYT107, and
high-frequency CYT107-treated patients, respectively.

CYT107 increased the absolute lymphocyte count
The major biological endpoint of the trial was to determine if CYT107 increases the absolute lymphocyte
count in patients with sepsis. Both low- and high-frequency treatment groups significantly increased the
absolute lymphocyte count over the course of the study (combined treatment effect: P < 0.001) (Figure 2,
B and C). At day 29, shortly after the end of therapy, both the low- and high-frequency CYT107-treated
patient groups had a marked and comparable 3.5- to 4.5-fold average increase in their absolute lymphocyte
counts compared with their initial values (Figure 2B). Specifically, at day 29, the absolute lymphocyte
counts were 2.98 ± 0.47 × 103 and 3.26 ± 0.72 × 103 lymphocytes/μl for the low- and high-frequency
CYT107-treated groups, respectively. After baseline adjustment, at day 29 the absolute lymphocyte count
among patients in the low- and high-frequency CYT107-treated groups was greater by 0.99 × 103 (95%
CI: 0.14, 2.13) and 1.30 × 103 lymphocytes/μl (95% CI: 0.20, 2.40), relative to the placebo-treated group
(combined treatment effect at day 29: P = 0.004) (Supplemental Figure 5). Note that there was a smaller
gradual increase in the absolute lymphocyte count in the placebo-treated group by the end of 4 weeks (Figure 2B). In this regard, patients who survive sepsis typically have a slow return of their absolute lymphocyte
count towards low-normal values while the absolute lymphocyte count usually remains low in patients who
ultimately die of sepsis (6). The increase in the absolute lymphocyte count in both CYT107-treated groups
approximated the upper limit of normal for most hospital laboratories, i.e., 3.5 × 103 lymphocytes/μl.

The increase in absolute lymphocyte count induced by CYT107 persists after therapy
Examination of the trajectory for the patient absolute lymphocyte counts showed that the ability of CYT107
to increase circulating lymphocytes persisted for at least 2–4 weeks following cessation of CYT107 therapy
insight.jci.org   https://doi.org/10.1172/jci.insight.98960
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Figure 5. CYT107 effect on absolute neutrophil and absolute monocyte counts. (A) The top right panel depicts the
patients’ absolute neutrophil counts (ANCs) with the shaded
gray area showing the normal counts for healthy individuals.
Septic patients had an increase in their ANCs that returned
to the normal range as their sepsis improved. There was an
overall treatment effect of CYT107 on ANC. Further, there
was an effect of high-frequency CYT107 to increase ANCs
at weeks 3, 4, and 6. The top left panel depicts patients’
absolute monocyte counts (AMCs). Patients’ AMCs were
generally within the normal range (shaded gray region)
during their sepsis and not different in the 3 treatment
groups. Statistical tests were conducted using a Wald-type
multiple-degree-of-freedom method. Values reported are
mean ± SEM. n = 10, 8, and 9 for placebo, low-frequency
CYT107, and high-frequency CYT107-treated patients,
respectively. *P < 0.05, **P < 0.01, ***P < 0.001. (B) The
lower left and lower right panels depict the ANCs and AMCs
respectively for each patient in the 3 treatment groups, i.e.,
placebo, low-frequency CYT107 group, and high-frequency
CYT107 group.

even in the patients who received only 3 or 4 doses of CYT107 (Figure 2, B and C). Specifically, at day 42,
the absolute lymphocyte count among patients in the low- and high-frequency CYT107 groups were, after
baseline adjustment, greater by 1.83 × 103 (95% CI: 0.57, 3.18) and 1.22 × 103 lymphocytes/μl (95% CI:
–0.01, 2.44), on average relative to the placebo-treated group (combined treatment effect at day 42: P = 0.001)
(Supplemental Figure 5). Note that although day 42 was the final time point for which absolute lymphocyte
count was quantified, it is likely that the CYT107-induced increase in lymphocytes persisted beyond day 42.
Previous clinical trials of CYT107 have demonstrated that the increase in absolute lymphocyte counts may
continue for as long as a year after CYT107 administration is discontinued (31).

CYT107 increased CD4+ and CD8+ T cells
The effect of CYT107 to increase the absolute lymphocyte count was paralleled by its effect to increase
CD4+ and CD8+ T cells, 2 major cell types comprising the absolute lymphocyte count (Figure 3). When
considered over the entire study period, CYT107 administration had a significant impact on the number
of circulating CD4+ and CD8+ T cells (combined treatment effects: P < 0.001 and P = 0.004, respectively).
At the end of the 28-day treatment regimen, both low- and high-frequency CYT107 dosing schedules
caused approximately 4-fold increases in CD4+ T cells compared with their baseline, pre-CYT107-therapy
values. Specifically, after baseline adjustment, at day 29, CD4+ T cell counts among patients in the lowand high-frequency CYT107-treated groups were greater by 0.32 × 103 (95% CI: –0.04, 0.68) and 0.28 ×
103 lymphocytes/μl (95% CI: –0.07, 0.63), on average relative to the placebo-treated group (combined
treatment effect at day 29: P = 0.021, Supplemental Figure 6A). CD8+ T cell counts among patients in the
low-frequency CYT107-treated group were not substantially greater (0.12 × 103 lymphocytes/μl; 95% CI:
–0.66, 0.90) at day 29, relative to the placebo-treated group. In the high-frequency CYT107 group at days
29 and 42, CD8+ T cell counts were greater by 0.76 × 103 (95% CI: –0.00, 1.52) and 1.39 × 103 lymphocytes/μl (95% CI: 0.37, 2.31), respectively, relative to placebo (combined treatment effects at days 29 and
42: P = 0.030 and P = 0.029, respectively; Supplemental Figure 6B).

CYT107 causes a transient decrease in CD4+ and CD8+ T cells prior to the sustained
increase
Pharmacodynamic studies demonstrate an initial, brief (24–48 hours) decrease in circulating lymphocytes following IL-7 administration. This decrease is coincident with upregulation of lymphocyte adhesion molecules
insight.jci.org   https://doi.org/10.1172/jci.insight.98960
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Figure 6. CYT107 increased lymphocyte proliferation. (A)
CYT107 increased the percentage of Ki67-positive CD4+ and
CD8+ T cells from approximately 10% at pre–CYT107 treatment to approximately 46% and 22%, respectively, on average for both CYT107 treatment groups. In contrast, there was
no significant change in the percentage of cells that were
Ki67 positive in placebo-treated patients. There was an overall treatment effect on Ki67 in both CD4+ and CD8+ T cells,
individually showing an effect of low-dose CYT107 therapy to
increase Ki67 in CD4+ T cells and both regimens to increase
Ki67 in CD8+ T cells as compared with placebo. Additionally,
in CD4+ T cells the low-frequency group displayed increased
Ki67 at days 4, 8, 22, 29, and 42, while in CD8+ T cells, the
high-frequency group showed increases at days 15 and 29,
and both treatment groups at day 8 as compared with placebo. *P < 0.05, **P < 0.01. Statistical tests were conducted
using a Wald-type multiple-degree-of-freedom method.
Values reported are mean ± SEM. n = 10, 8, and 9 for placebo,
low-frequency CYT107, and high-frequency CYT107-treated
patients, respectively. (B) The effect of CYT107 on lymphocyte proliferation, as determined by flow cytometric quantification of Ki67, is provided for each patient. US study patients
had flow cytometric quantification of Ki67 for 6 weeks, while
French study patients had flow cytometric quantification out
to 4 weeks only. Baseline adjustment reflects the difference
between study day values and the predosing values.

and homing of lymphocytes from the circulation and into various tissues such as skin and intestine, and to sites
of infection (39, 40). In the present study, at day 4 after initiation of CYT107 treatment, CD4+ and CD8+ T cell
counts in both low- and high-frequency treatment groups trended in the negative direction being, on average,
31.4% and 25.4% lower, respectively, than their day 0 values (Figure 4). In contrast, in placebo-treated patients,
absolute numbers of CD4+ and CD8+ T cells increased by 14.4% and 27.9%, respectively. In comparing
CYT107 treatment groups with placebo, the low-frequency CYT107-treated group had a significant reduction
in CD8+ T cells by 0.10 × 103 lymphocytes/μl (95% CI: 0.03, 0.19; P = 0.009), on average, at day 4 (Figure 4).

CYT107 effect on absolute neutrophil, monocyte, and B cell counts
The effect of CYT107 on patients’ absolute neutrophil counts (ANCs) and absolute monocyte counts
(AMCs) was examined. Early during the course of their sepsis, both CYT107- and placebo-treated patients
had increased ANCs compared with normal healthy volunteers (Figure 5 and Supplemental Figure 6, C and
D). The ANCs returned to normal values later in the patients’ recovery. There was no effect of CYT107 on
ANCs through week 2. However, there was an effect of the high- but not low-frequency dosing regimen of
CYT107 at week 3 to increase ANCs (P < 0.01). In addition to the overall effect, the high-dose group showed
increases of 13.16 × 103 cells/μl (95% CI: 5.74, 20.58), 7.55 × 103 cells/μl (95% CI: 2.38, 12.72), and 5.31
× 103 cells/μl (95% CI: 0.28, 10.33), at days 22 (P < 0.001), 29 (P = 0.004), and 42 (P = 0.038), respectively
(Figure 5 and Supplemental Figure 6D). The statistical difference in ANCs in the CYT107-treated patients
versus placebo-treated patients persisted until week 6; however, at that time, the averaged ANCs were within
normal limits (shaded area) and quantitative differences between groups were small and of questionable
biologic significance. The AMCs were similar for CYT107- and placebo-treated patients and were generally within the normal range for healthy volunteers, (Figure 5 and Supplemental Figure 6C). The effect of
CYT107 on the absolute number of B cells was examined in a subset of patients (n = 13). There was no
apparent effect of CYT107 to increase the absolute number of B cells (Supplemental Figure 7) and these
results are in agreement with other clinical studies of CYT107-treated patients (30).

CYT107 increased cell cycling
To evaluate potential mechanisms for the effect of CYT107 to increase lymphocyte counts, Ki67 was measured
in CD4+ and CD8+ T cells by flow cytometry. CYT107-treated patients had a brisk increase in the percentage of
Ki67-positive CD4+ and CD8+ T cells occurring within 4–7 days after starting CYT107 (Figure 6) (combined
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Figure 7. CYT107 decreased IL-7 receptor α (CD127) expression. (A) The IL-7 receptor is composed of a common γ
chain and the IL-7 receptor α (CD127). CD127 is known to be
transiently downregulated after administration of IL-7. Flow
cytometry showed that there was a decrease in CD4+ and
CD8+ T cell expression of IL-7 receptor α in patients treated
with both low- and high-frequency treatment regimens of
CYT107 versus placebo at day 4. *P < 0.05. Statistical tests
were conducted using a Wald-type multiple-degree-offreedom method. Values reported are mean ± SEM for the
3 different treatment groups, i.e., placebo, low-frequency
CYT107, and high-frequency CYT107. n = 10, 8, and 9 for
placebo, low-frequency CYT107, and high-frequency CYT107treated patients, respectively. (B) The lower left and lower
right panels depict the percentages of CD4+ and CD8+ T cells
positive for the IL-7 receptor α respectively for each patient
in the 3 treatment groups, i.e., placebo, low-frequency
CYT107 group, and high-frequency CYT107 group. US study
patients had flow cytometric quantification of Ki67 for 6
weeks, while French study patients had flow cytometric
quantification out to 4 weeks only. Baseline adjustment
reflects the difference between study day values and the
predosing values.

treatment effect: CD4+ T, P = 0.006; CD8+ T, P = 0.010). The percentage of Ki67-positive CD4+ T cells increased
from approximately 10% at pre-CYT107 treatment to approximately 57.6% and 37.9% for low- and high-frequency treatment groups, respectively, versus approximately 15% for placebo at day 8. At day 4, the percentage
of Ki67-positive CD4+ T cells was higher in the low-frequency CYT107-treated group compared with placebo, by
23.6% (95% CI: 6.8, 40.5; P = 0.006) on average. Significant differences were also present on days 8 (P < 0.001),
22 (P = 0.053), 29 (P = 0.033), and 42 (P = 0.039). After adjusting for baseline, there was insufficient evidence of
differences in Ki67-positive CD4+ T cells in the high-frequency CYT107-treated patients versus placebo. CYT107
had a significant impact on Ki67-positive CD8+ T cells (combined treatment effect: P = 0.010). At day 8, Ki67positive CD8+ T cells were greater by 17.1% (95% CI: 6.78, 27.3; P = 0.001) and 14.2% (95% CI: 4.2, 24.1; P =
0.005) in the low- and high-frequency CYT107 groups, respectively, on average versus placebo. Significant differences were also present on day 15 (P = 0.010) for the high-frequency treatment group (Figure 6).

CYT107 decreased IL-7 receptor α (CD127) expression
IL-7 receptor α (CD127) is a subunit of the IL-7 receptor complex. Studies show that administration of
IL-7 to patients results in a rapid and transient downregulation of IL-7 receptor α (23, 32). In the present
study, there was significant evidence that CYT107 affected CD127 expression on both CD+4 and CD8+ T
cells (combined treatment effect: P = 0.002 and P < 0.001, respectively) (Figure 7). In the low-frequency
IL-7 group at day 4, there was a significant decrease in CD127-positive CD4+ and CD8+ T cells, by 19.1%
(95% CI: 4.4, 33.9; P = 0.011) and 26.04% (95% CI: 8.5, 44.4; P = 0.004) respectively, versus placebo. Insufficient evidence was found in comparing the high-frequency group versus placebo.

CYT107 increases early lymphocyte activation markers but not PD-1 expression
We also examined the effect of CYT107 on 2 early T cell activation markers, i.e., CD38 and HLA-DR, and
on programmed cell death 1 (PD-1; CD279). There was significant evidence of a combined treatment effect
of CYT107 on CD38 in CD4+ T cells (P = 0.004) (Figure 8A). There was no statistically significant effect of
CYT107 on CD38 expression in CD8+ T cells (Supplemental Figure 7A). There was insufficient evidence
for a combined treatment effect of CYT107 on HLA-DR expression. Although there was no overall effect
by the high-frequency dosing regimen of CYT107 on HLA-DR in CD4+ T cells, the effect to increase the
percentage of cells expressing HLA-DR did approach statistical significance at days 7 and 22, with an
increase from approximately 5% to an additional 2.20% (95% CI: –0.19, 4.59; P = 0.07) and 2.13% (95%
insight.jci.org   https://doi.org/10.1172/jci.insight.98960
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Figure 8. CYT107 increased early activation markers in CD4+ T cells.
(A) The expression of CD38 and HLA-DR increases during T cell activation. The CYT107 treatment effect for CD38, considered for the entire
duration of the study, was significant for low-frequency dosing regimen
CYT107 (red color) in CD4+ T cells (upper left panel). Additionally, the
high-frequency dosing regimen for CYT107 (upper right panel, blue
color) showed an increase in HLA-DR expression in CD4+ T cells, which
approached significance at days 8 (P = 0.07) and 22 (P = 0.055). *P <
0.05. Statistical tests were conducted using a Wald-type multipledegree-of-freedom method. Values reported are mean ± SEM. n = 10, 8,
and 9 for placebo, low-frequency CYT107, and high-frequency CYT107treated patients, respectively. (B) The lower left and lower right panels
depict the effect of CYT107 on CD38 and HLA-DR expression respectively
for each patient in the 3 treatment groups, i.e., placebo, low-frequency
CYT107, and high-frequency CYT107. Baseline adjustment reflects the
difference between study day values and the predosing values.

CI: –0.05,4.3; P = 0.055), respectively (Figure 8B). CYT107 did not increase HLA-DR expression on CD8+
T cells (Supplemental Figure 8A). There was insufficient evidence of an overall effect of either low- or highfrequency regimens of CYT107 on PD-1 expression (Supplemental Figure 8B). The gating strategy used
for flow cytometric identification of cell surface markers is illustrated in Supplemental Figures 9 and 10.

Incidence of secondary infections in the treatment groups
The development of hospital-acquired secondary infections was evaluated by a 3-member panel of experienced intensive care physicians using the Center for Disease Control criteria for healthcare-associated
infections. The panel members were blinded to patient identity and treatment group. Four of 10 (40%)
of placebo-treated patients versus 5 of 17 (30%) of CYT107-treated patients developed hospital-acquired
infections and this difference was not statistically significant (P = 0.72, Fisher’s exact test). Sites of secondary infections included ventilator-associated pneumonia, ventilator-associated tracheobronchitis, wound
infections, peritonitis, mediastinitis, knee joint infection, and urinary tract infection.

Mortality in CYT107- and placebo-treated patients
Patients were followed for 120 days after study entry. At the end of the 28-day treatment period, 1 of 10
(10%) placebo-treated patients and 2 of 17 (12%) of CYT107-treated patients had died (P = 0.855, Fisher’s
exact test) (Table 2). At day 120, 2 of 10 (20%) of placebo-treated patients and 5 of 17 (29%) of the CYT107treated patients had died and this difference was not statistically significant (P = 0.687, Fisher’s exact test).
Causes of death, length of stay in the ICU, and important clinical details that impacted mortality in the
patient population are presented in Table 2. Importantly, failure of source control and delayed recognition of
ongoing sources of sepsis were contributing factors in mortality in a number of patients. This issue of lack of
source control is likely due to the preponderance of surgical ICU patients with sepsis included in this study.
One CYT107-treated patient with severe preexisting coronary artery disease and third-degree heart block
recovered from his admission for sepsis due to necrotizing fasciitis but died 63 days later of complications
from myocardial infarction. One patient in the placebo-treated group died of delayed complications from
severe hypoglycemic brain injury when the family decided to change to comfort measures only.

Pharmacokinetics for CYT107
CYT107 plasma levels were measured at 1, 3, 5, 9, and 24 hours after intramuscular administration at day
1 and day 22 (blue and red curves, respectively; Figure 9). At day 1, the Cmax 443 ng/ml was observed at 9
hours with an AUC of 7,472.6 pg/ml⋅h. At day 22, the Cmax 420 ng/ml was observed at 5 hours with an
AUC of 4,358.3 pg/ml⋅h.
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Table 2. Mortality for CYT107- and placebo-treated patients
Treatment

Placebo 20% (2 out of 10)

CYT107A 29% (5 out of 17)

Age

Sex

Diagnosis

44

M

Urinary tract infection

41

76

71
61

M
M

17
12

17
12

65
70

M
M

Fournier’s gangrene
Esophageal leak with mediastinitis
following radiation and esophageal resection
Mediastinitis following cardiac surgery
Peritonitis

45
14

45
14

80

F

63

67

71

M

42

63

Ventilator-associated pneumonia
following motor vehicle accident
Fournier’s gangrene complicated by
myocardial infarction and third-degree
heart block

Days ICU Day expiration

Notes

Persisting coma secondary to
severe hypoglycemia
multiple organ failure
Surgical failure (lack of
source control)
mesenteric ischemia
Multiple organ failure with
unrecognized bowel leak
Prolonged peritonitis due to
unrecognized bile duct injury
Cardiac arrest secondary to
myocardial ischemia

Final day of CYT107 therapy was day 25.

A

Immunogenicity for detection of antibodies against CYT107
Immunogenicity studies for detection of antibodies against the recombinant human CYT107 employed in
this trial were performed at days 0, 11, 22, and 60 for all 17 CYT107-treated patients and were negative for
antibody detection (see supplemental material).

Discussion
The present study of CYT107 in patients with sepsis has several potentially unique aspects. First, CYT107’s
immune-boosting effects stand in marked contrast to the overwhelming majority of previous clinical trials
in sepsis that have employed therapies to block inflammation and the host immune response (20, 21, 41–
45). A second potentially unique aspect is that it represents the first trial to our knowledge that focuses on
reversing sepsis-induced defects in adaptive immunity, i.e., CD4+ and CD8+ T cells. The few prior immunoadjuvant drug therapy trials that sought to enhance immunity in septic patients employed cytokines
and growth factors, e.g., IFN-γ, G-CSF, and GM-CSF, to increase the number and function of monocytes,
macrophages, and neutrophils, which are key cellular components of the innate immune system. In addition to suppressing innate immunity, sepsis significantly impairs adaptive immunity by causing extensive
apoptotic death and dysfunction of CD4+ and CD8+ T cells, the key cellular targets of CYT107 (2–5).
In the current study, over 60% of septic patients had an initial CD4+ T cell count of less than 200 cells/
μl, one of the criteria used to define AIDS (Figure 4). The potential impact of low CD4+ T cell counts in
sepsis is underscored by reports demonstrating a direct correlation between decreased CD4+ T cells and
increased incidence of opportunistic infections and death (12, 13). Furthermore, numerous investigators
have demonstrated a close correlation between low absolute lymphocyte counts and increased mortality
in sepsis (5–8). Collectively, these reports, considered together with investigations demonstrating that preventing sepsis-induced lymphocyte depletion improves survival (25, 26, 15–18), underscore the potential
significance of the present findings in which CYT107 caused a 3- to 4-fold increase in absolute lymphocyte counts and CD4+ and CD8+ T cells in patients with septic shock (Figures 2B and 3).
The profound decrease in circulating lymphocytes in sepsis is mirrored by concomitant decreases in
tissue lymphocytes in spleens and other organs in which the number of CD4+ and CD8+ T cells is often less
than 10%–30% of that present in organs from nonseptic patients (1, 46). Although the present study did not
address the effect of CYT107 on tissue lymphocytes, numerous studies in animals, including nonhuman
primates treated with CYT107 demonstrate that the robust increase in CD4+ and CD8+ T cells present in
the blood is accompanied by a significant increase in lymphocytes in spleens and lymph nodes as well (35).
Furthermore, HIV-infected patients who had incomplete immune restoration despite receiving antiretroviral therapy and who were treated with CYT107 had markedly increased numbers of CD3+ T cells repopulating their lymphocyte-depleted colons (47). Combined computerized tomography scanning and positron
emission tomography (CT-PET) of cancer patients treated with CYT107 showed spleen, mediastinal, and
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Figure 9. Pharmacokinetics of CYT107. CYT107
(human recombinant CYT107) was measured in
patients EDTA-3K plasma at 1, 3, 5, 9, and 24 hours
after intramuscular administration. The blue curve
shows the kinetics after the first administration at
day 1 and the red curve after administration at day 22.
Values reported are mean ± SEM. n = 17 patients on
day 1 and n = 9 patients on day 22.

abdominal lymph node enlargement associated with increased cellular metabolic activity in these organs
(35). Therefore, the increase in circulating immune effector cells in septic patients treated with CYT107
likely also occurred systemically in the patients’ various immune tissues including spleen and lymphoidassociated aggregates in lung and gut.
A seemingly paradoxical effect of CYT107 that has been reported in previous clinical studies of
CYT107 is its action to cause an initial drop in circulating lymphocytes. This decrease in circulating
lymphocytes lasts 24–72 hours before rebounding (39, 40). Our data showed similar findings, with an
early decrease in CD8+ T cell counts and a strong trend toward decreased CD4+ T cell counts on day
4 in the CYT107-treated patients (Figure 4). Studies in healthy rhesus macaques established that the
transient decrease in circulating T cells that occurs immediately after the initial dose of CYT107 is
due to recruitment of lymphocytes from the bloodstream into various tissues including gut, skin, and
lymph nodes (39, 40). The presumed mechanism for this trafficking of lymphocytes from the circulation into these tissues is IL-7’s effect to upregulate expression of numerous chemokines and adhesion
molecules, e.g., CXCR4, CCR7, α4β7, LFA-1, and VLA-4, on CD4+ and CD8+ T cells (48–51). This
effect of IL-7 to activate lymphocytes to increase expression of adhesion molecules and chemokines is
also the likely explanation for the skin rashes that occurred in many CYT107-treated patients. It is possible that CYT107’s effect to increase lymphocyte adhesion molecule expression will be advantageous
in sepsis by resulting in increased lymphocyte trafficking to sites of infection. Inflammation occurring
at sites of infection causes endothelial and parenchymal cells to upregulate the corresponding receptor
and/or ligand partners for the adhesion molecules and chemokines expressed on the CD4+ and CD8+
T cells. The overall effect will be migration of immune effector cells to sites of infection and enhanced
pathogen killing. In this regard, studies demonstrated that mice with viral hepatitis that were treated
with CYT107 had a 3- to 4-fold increase in the number of CD4+ and CD8+ T cells present in the infected
liver and an accompanying dramatic improvement in viral clearance compared with control mice (52).
The increase in lymphocytes in CYT107-treated septic patients is likely due to 2 independent mechanisms. First, as is well documented in multiple clinical trials, CYT107 acts to induce proliferation of CD4+
and CD8+ T cells (31–33, 50). In the current study, the effect of CYT107 to stimulate lymphocyte proliferation is evidenced by the increase in the cell cycle marker Ki67 in CD4+ and CD8+ T cells of patients treated
with CYT107 versus placebo (Figure 5). A second mechanism for the increase in CD4+ and CD8+ T cells
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in septic patients treated with CYT107 is the potent antiapoptotic effect of IL-7 (25–29). IL-7 increases
antiapoptotic Bcl-2 family members and decreases proapoptotic Bcl-2 family members (53). Previously,
our laboratory utilized a mouse peritonitis model of sepsis to demonstrate that CYT107 decreased apoptosis of splenic and lymph node naive, central memory, and effector memory CD4+ and CD8+ T cells by
approximately 50% at 24 hours (26). This antiapoptotic effect was associated with an increase in Bcl-2 and
a decrease in proapoptotic PUMA. Furthermore, 2 ex vivo studies in septic shock patients’ cells showed
that IL-7 restored lymphocyte proliferation in response to anti–CD2-CD3-CD28 antibody–coated bead
stimulation (28, 29). This finding was associated with increased Bcl-2 expression (28) and mTOR pathway
reactivation leading to aerobic glycolysis restoration and thus to improved lymphocyte proliferation (29).
Important findings in the present study are data showing that the increase in CD4+ and CD8+ T cells
is maintained for the entire duration of the study observation, which was at least 2–4 weeks after cessation
of CYT107 therapy (Figures 2B, 2C, and 3). These data are in agreement with numerous clinical studies
reporting that the effect of CYT107 to increase lymphocytes persists for several months after the end of
CYT107 administration (32, 35). This effect of CYT107 to sustain the number of immune effector cells for
weeks to months after stopping therapy is likely to be particularly beneficial in sepsis. Many patients survive their initial infection only to develop lethal secondary hospital-acquired infections. These nosocomial
infections are a major cause of the approximate 30%–40% additional increase in mortality in patients with
sepsis that occurs between days 28 and 90 (54). There was a nonstatistically significant trend toward a 25%
decrease in secondary hospital-acquired infections in patients treated with CYT107 compared with patients
receiving placebo.
An interesting finding in the present study is the difference in patient response to low- versus highfrequency CYT107. In some instances, the low-frequency dosing regimen of CYT107 had a more
robust effect than the high-frequency dosing regimen (e.g., Figures 6 and 7). We speculate that these
differences are due to patient heterogeneity both in extent and type of comorbidities, sites of infection,
and infecting pathogens. The fact that some differences were seen within or shortly after the first week
(when both the low- and high-frequency CYT107 treatment groups received the same number of doses,
i.e., exact same amount of CYT107) suggests that patient heterogeneity and changes in patient clinical status rather than CYT107 was responsible for the observed effect. Similarly, we speculate that the
increase in ANCs that was observed in patients treated with the high-frequency CYT107 dose regimen
may have been due in part to patient heterogeneity or to changes in patient clinical status rather than
an actual effect of CYT107. Neutrophils do not express the IL-7α receptor and previous clinical trials
of CYT107 have not reported increases in neutrophil counts (55). The fact that CYT107 had no effect
on the ANCs for the first 2 weeks of therapy and that there were very minor differences in ANCs in
CYT107- and placebo-treated patients by week 6 (Figure 5) makes it less likely that CYT107 was having
a major effect on the number of circulating neutrophils.
In a very real sense, the immune system is like an orchestra that works optimally when all its diverse
members are functioning harmoniously. There is extensive cross talk between the various cellular components of the innate and adaptive immune systems. CD4+ helper T cells are particularly essential for
proper functioning of host immunity because, as their name indicates, they help to stimulate and instruct
the phenotypic response of many other types of innate and adaptive immune effector cells. IL-7 has been
called the “maestro of the immune system” because of its effect to activate and induce proliferation of
these CD4+ helper T cells (56). In this regard, CD4+ T cells from patients treated with CYT107 had an
increase in the proliferation marker Ki67 and the activation marker CD38 (Figures 6 and 7). As noted
previously, the early decrease in circulating CD4+ T cells after initiation of CYT107 therapy is also evidence of CD4+ T cell activation by CYT107. Importantly, CYT107 also increases CD4+ and CD8+ T cell
IFN-γ production in both animal models of sepsis and in studies of peripheral blood mononuclear cells
from patients with sepsis (25–29). IFN-γ is a potent activator of monocytes and macrophages, key components of the innate immune system that play an essential role in pathogen killing. Although we did not
investigate them, a relatively recently discovered mechanism of action of IL-7 is to increase the number
and function of innate lymphoid cells (ILCs) and mucosal-associated invariant T cells (MAITs) (57, 58).
ILCs and MAITs, which express the IL-7-α receptor (CD127), are present in high concentrations in lung
and gastrointestinal tract. These cells respond rapidly to invading pathogens that enter the host through
the pulmonary or gastrointestinal system by producing key cytokines that activate protective antimicrobial
immune defenses. The fact that studies demonstrate that IL-7 causes a rapid improvement in survival in
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selected animal models of sepsis within 24–48 hours after its administration may be due to an effect of
IL-7 to activate these early responding ILCs and MAITs (26, 59).
Unlike some members of the common γ-chain family of cytokines, CYT107 was well tolerated without
evidence of inducing a cytokine storm, exacerbating underlying sepsis-induced inflammation, or worsening existing organ injury (Supplemental Figures 1–3) (23, 24, 30–34). CYT107 has now been reported to
be safe in almost 400 adult and pediatric patients with a diversity of disorders including HIV, hepatitis C,
cancer, idiopathic lymphopenia, and life-threatening progressive multi-focal leukoencephalopathy (30–37).
Furthermore, doses of CYT107 up to 6 times higher than the dose used in this investigation have been
administered to oncology patients and reported to be well tolerated (34). One likely explanation for the
excellent safety profile of CYT107 is the unique nature of the IL-7 receptor complex, which is partly composed of the IL-7 receptor α subunit (CD127) (23). Administration of CYT107 results in a rapid transitory
decreased expression of the IL-7 receptor α chain, thereby rendering the cell less responsive to additional
CYT107. Downregulation of IL-7 receptor α presumably prevents overstimulation of CD4+ and CD8+ T
cells. A statistically significant decrease in IL-7 receptor α expression was observed (Figure 6). The only
adverse effect of CYT107 in the present study was a grade 2–3 rash that resulted in early discontinuation of
CYT107 dosing in 4 of 17 patients.
The failure of many previous therapeutic trials has generated widespread skepticism in the field toward
potential new therapeutic approaches in sepsis (21, 42–45, 57–59). Similar skepticism toward immunotherapy was present in the oncology field prior to the extraordinary advances in cancer treatment that
occurred with the discovery of checkpoint inhibitors. Remarkably, the underlying mechanisms responsible
for immunosuppression are highly similar in both sepsis and cancer (60, 61). Given the common mechanisms of immunosuppression in the 2 disorders, it is not surprising that anti–PD-1, the most widely used
and successful immunotherapy in oncology, is also highly effective in restoring CD4+ and CD8+ T cell
function and improving survival in animal models of sepsis (62–66). Anti–PD-1 (nivolumab) is currently in
clinical trials in patients with sepsis (NCT02960854). This success of anti–PD-1, a second immunotherapeutic agent whose primary target is blocking a negative regulator of T cells, provides additional sound
theoretical support for the potential efficacy of CYT107 that, like anti–PD-1, acts primarily to restore the
number and function of T cells. Both CYT107 and anti–PD-1 represent a transformational therapeutic
approach by targeting a hallmark of sepsis, which is massive loss in T cells and the accompanying defect in
adaptive immunity in sepsis.
In conclusion, CYT107 represents a promising and potentially novel approach to sepsis and is the first
immuno-adjunctive therapy to our knowledge directed at restoring adaptive immunity in this disorder.
Although a larger trial of CYT107 in sepsis is needed to confirm findings in the present study, CYT107
appears safe and effective in reversing the profound loss in CD4+ and CD8+ immune effector cells, a critical pathophysiologic mechanism in sepsis. CYT107 was also effective at increasing T cell activation and
potentially assisting in trafficking of CD4+ and CD8+ T cells to sites of infection. The effect of CYT107
to maintain lymphocyte counts continued for several weeks after cessation of drug therapy. Therefore, the
beneficial effects of CYT107 on host immunity persist during the time at which surviving patients are highly susceptible to secondary nosocomial infections. The results of the present trial considered in conjunction
with CYT107’s demonstrable safety record in other critically ill patients and its efficacy in life-threatening
viral infections make a compelling case for a definitive trial of CYT107 in this highly lethal disorder.

Methods
Study design. This study was a prospective, randomized, double-blind, placebo-controlled trial of recombinant human IL-7 (CYT107) in patients with septic shock and severe lymphopenia. Twenty-seven patients
at academic sites in France and the United States received CYT107 (in either low- or high-frequency regimens) or placebo for 4 weeks. Primary aims were to determine the safety of CYT107 in sepsis and its ability
to reverse lymphopenia. Based on the results of prior trials in patients with HIV or malignancies, a power
calculation was performed. A sample size of 10 subjects per trial arm was found to have greater than 85%
power to detect an equal or more extreme treatment effect to reverse lymphopenia.
Study deviations. IL-7 administration was discontinued on 4 patients due to a grade 2–3 rash formation at injection site (see Results section on patient safety). Study enrollment was halted at 27 patients
out of a planned enrollment of 30 patients because of requirement for additional drug stability testing
that was due at this time.
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Inclusion criteria. Patients had to be between the ages of 18 and 80, have 2 or more criteria for systemic inflammatory response syndrome (SIRS), have a clinically or microbiologically suspected infection
(38), a SOFA score of 2 or higher at 48–120 hours after ICU admission, require vasopressor treatment,
and an absolute lymphocyte count of 900 cells/μl or lower within 24 hours of a signed informed consent
(see supplemental materials).
Exclusion criteria. Patients currently undergoing chemo- or radiotherapy because of cancer, current or a
history of hematologic malignancy or lymphoma, cardiopulmonary resuscitation within 4 weeks, history
of or current evidence of an autoimmune disorder, organ transplant recipient, HIV/AIDS, hepatitis B or
C; receiving corticosteroids at a dose of 300 mg or higher of hydrocortisone/day, receiving biologics that
block cytokines were excluded (see supplemental materials).
Thirty-three patients were enrolled into the study but only 27 patients were dosed with drugs (Figure
1). Three patients who were enrolled were not dosed because of marked clinical deterioration with likely
impending demise occurring between the time of enrollment and the time of planned administration of
drug (CYT107 or placebo). Two patients who consented were not dosed because of rapid clinical improvement within 24–48 hours with resolution of signs of sepsis and SOFA scores less than 2. One patient who
was consented was not dosed because of discovery of an exclusion criterion that had been missed earlier.
CYT107 preparation and drug dosing. CYT107, which has been extensively used in other clinical trials,
was employed (30, 31). Patients were randomized by allocation to a permuted-block randomization (block
size of 3 and allocation ratio of 1:1:1, stratified by country, and dosed using 3 different administration
protocols: CYT107 high frequency, CYT107 low frequency, and placebo. CYT107 or placebo was administered by intramuscular injection. If the patient’s platelet count was below 35,000 per mm3 or the international normalized ratio was 3.5 seconds or higher, CYT107 was administered by subcutaneous injection.
All patients were injected twice per week for 4 weeks. All CYT107 patients received 10 μg/kg of CYT107
twice in the first week, followed by: the same dosage, twice per week for the high-frequency regimen; and
once per week followed by an injection of placebo (NaCl 0.9%) midweek for the low-frequency regimen.
The control, or placebo, group was given placebo (NaCl 0.9%) twice per week.
The statistician, local pharmacist, and the central laboratory in charge of pharmacokinetic (PK)/
immunogenicity analysis were the only unblinded entities.
Blood samples were drawn for flow cytometric analysis prior to the first dose (day 0), following dosing on
days 4, 8, 15, and 22, and then on days 29 and 42. PK samples were drawn on the initial dosing day and on
day 22. Immunogenicity samples were collected prior to initial dosing (day 0), and then on days 11, 22, and 60.
Flow cytometry. Flow cytometric analysis was performed as previously described (28, 46) — see supplemental materials and methods. Cells stained with cocktails examining only surface markers were fixed in
1% paraformaldehyde, while cells stained for intracellular markers were first surface stained, permeabilized,
and stained for intracellular markers (Ki67). Acquisitions were analyzed with FlowJo v 10.2 (FlowJo, LLC).
Number of CD4+ and CD8+ T cells. CD4+ and CD8+ T cell numbers were calculated using flow cytometric
results. First, the lymphocytes were gated on FSC × SSC, and then the percentages of CD3+CD4+ cells and
CD3+CD8+ cells were determined (Supplemental Figure 5 provides the gating strategy). The frequency of
parent percentages was multiplied by absolute lymphocyte count and the product was used as the number
of CD4+ and CD8+ T cells, respectively.
Molecules of equivalent soluble fluorochrome (MESF). MESF was calculated by obtaining the population’s
geometric mean fluorescence intensity (GMFI) and plotting it against values derived from Quantum PE
(monocyte HLA-DR, CD279) or Quantum APC (Ki-67, CD127) beads (Bangs Lab) in Microsoft Excel.
Quantification of circulating cytokines IL-6, IL-10, and TNF-α via ELISA. Cytokine kits for TNF-α, IL6,
and IL-10 were obtained from Biolegend and R&D Systems — see supplemental materials and methods.
Assays were performed exactly as per the manufacturer’s instructions and as previously described (46).
PK and immunogenicity analysis. PK and immunogenicity testing were carried out by Eurofins ADME
BIOANALYSES.
For PK analysis, CYT107 was measured in EDTA-3K plasma samples using a validated DIACLONE
ELISA kit (catalog 851.680.020). The method includes a capture CYT107 antibody and a biotinylated
detection antibody. The results obtained during the validation studies are reported in a Eurofins full bioanalytical report.
For immunogenicity testing, anti-CYT107 antibodies were detected in heparin-Li plasma samples. Briefly
the ability of plasma samples to bind CYT107 are compared with a positive anti–rh-CYT107 IgG (Preprotech)
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in a preliminary screening test aimed at detecting anti-CYT107 binding antibodies. Positive samples from this
screening assay are then spiked with CYT107 to displace and detect the specificity of the binding activity.
Statistics. Comparisons across treatment groups at baseline were performed using the Kruskal-Wallis
test and Fisher’s exact test. Each outcome variable (e.g., absolute lymphocyte count) was baseline adjusted
by subtracting the corresponding baseline value. Baseline-adjusted outcomes were then analyzed using
linear mixed-effects regression, adjusting for study day (as a categorical variable), treatment group, and the
interaction between study day and treatment group. All figures show values plotted as mean ± SEM (see
supplemental methods for additional details).
Study approval. This double-blind, randomized, placebo-controlled phase IIb trial of CYT107 was
conducted at 4 academic sites, with 2 sites in the United States (Vanderbilt University and Washington
University ) and 2 sites in France (University Hospital of Limoges and Edouard Herriot Hospital). Following FDA approval of the study, the Institutional Review Boards at Vanderbilt University (IRB 152001)
and Washington University (IRB 20161106) approved the protocols. For France, the study protocol was
approved by the CPP and ANSM. All patients or their legal representatives gave written informed consent
prior to study inclusion.
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